房颤患者NOAC治疗期间缺血性脑血管事件的原因与危险因素
这项病例对照研究纳入713例NOAC治疗期间发生急性缺血性脑血管事件的房颤患者和700例无事件对照,发现63.9%事件按A-S-C-O-D分类为心源性栓塞;超说明书低剂量NOAC、心房增大、高脂血症和CHA2DS2-VASc评分升高与事件风险增加相关,阵发性房颤则呈负相关。
要点
- NOAC治疗期间发生的缺血性事件多数为心源性栓塞,但并非全部。
- 超说明书低剂量NOAC、心房增大、高脂血症和高CHA2DS2-VASc评分增加事件风险。
- 阵发性房颤与缺血事件风险降低相关。
核心结论
- NOAC治疗期间发生脑血管事件的房颤患者中,事件多数但并非全部为心源性栓塞,超说明书低剂量、心房增大、高脂血症和高CHA2DS2-VASc评分与事件风险增加相关。
研究设计与样本
- 病例对照研究,纳入713例NOAC治疗期间发生急性脑血管缺血事件的房颤患者(641例缺血性卒中、72例短暂性脑缺血发作)和700例无事件对照。
主要发现
- 455例(63.9%)复发卒中按A-S-C-O-D分类为心源性栓塞。
- 多变量分析显示超说明书低剂量NOAC的OR为3.18(95%CI 1.95-5.85)。
- 心房增大的OR为6.64(95%CI 4.63-9.52),高脂血症的OR为2.40(95%CI 1.83-3.16)。
- CHA2DS2-VASc评分每增加1分的OR为1.72(95%CI 1.58-1.88)。
- 阵发性房颤与缺血事件呈负相关,OR为0.45(95%CI 0.33-0.61)。
临床怎么用
- 对NOAC治疗的房颤患者应关注超说明书低剂量使用、心房增大、高脂血症和高CHA2DS2-VASc评分等危险因素。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Background and Purpose- Despite treatment with oral anticoagulants, patients with nonvalvular atrial fibrillation (AF) may experience ischemic cerebrovascular events. The aims of this case-control study in patients with AF were to identify the pathogenesis of and the risk factors for cerebrovascular ischemic events occurring during non-vitamin K antagonist oral anticoagulants (NOACs) therapy for stroke prevention. Methods- Cases were consecutive patients with AF who had acute cerebrovascular ischemic events during NOAC treatment. Controls were consecutive patients with AF who did not have cerebrovascular events during NOACs treatment. Results- Overall, 713 cases (641 ischemic strokes and 72 transient ischemic attacks; median age, 80.0 years; interquartile range, 12; median National Institutes of Health Stroke Scale on admission, 6.0; interquartile range, 10) and 700 controls (median age, 72.0 years; interquartile range, 8) were included in the study. Recurrent stroke was classified as cardioembolic in 455 cases (63.9%) according to the A-S-C-O-D (A, atherosclerosis; S, small vessel disease; C, cardiac pathology; O, other causes; D, dissection) classification. On multivariable analysis, off-label low dose of NOACs (odds ratio [OR], 3.18; 95% CI, 1.95-5.85), atrial enlargement (OR, 6.64; 95% CI, 4.63-9.52), hyperlipidemia (OR, 2.40; 95% CI, 1.83-3.16), and CHA2DS2-VASc score (OR, 1.72 for each point increase; 95% CI, 1.58-1.88) were associated with ischemic events. Among the CHA2DS2-VASc components, age was older and presence of diabetes mellitus, congestive heart failure, and history of stroke or transient ischemic attack more common in patients who had acute cerebrovascular ischemic events. Paroxysmal AF was inversely associated with ischemic events (OR, 0.45; 95% CI, 0.33-0.61). Conclusions- In patients with AF treated with NOACs who had a cerebrovascular event, mostly but not exclusively of cardioembolic pathogenesis, off-label low dose, atrial enlargement, hyperlipidemia, and high CHA2DS2-VASc score were associated with increased risk of cerebrovascular events.
引用
- Paciaroni M, Agnelli G, Caso V, et al. Causes and Risk Factors of Cerebral Ischemic Events in Patients With Atrial Fibrillation Treated With Non-Vitamin K Antagonist Oral Anticoagulants for Stroke Prevention. Stroke. 2019. PMID: 31234756. doi:10.1161/STROKEAHA.119.025350
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。